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BACKGROUND: The significance of BRAF mutations, microsatelite instability (MSI) status and cyclin D1 expression in patients with
metastatic colorectal cancer (mCRC) was evaluated.
METHODS: Primary tumours from 144 patients treated for mCRC were assessed for BRAF (V600E) mutation, MSI status and cyclin D1.
The data were correlated with progression-free survival (PFS) and overall survival (OS).
RESULTS: BRAF mutations were detected in 10 (out of 22, 45%) patients with MSI-H tumours compared with 2 (out of 122, 1.6%) in
those with microsatellite stable tumours (Po0.001). The presence of BRAF mutations was correlated with cyclin D1 overexpression
(7 out of 26 patients, 58% vs 5 out of 118 patients, 14%; P¼0.001). Patients with BRAF-mutated primary tumours had a significantly
decreased PFS (2.7 vs 9.8 months; Po0.001) and median OS (14 vs 30 months; Po0.001) than patients with wild-type (wt) tumours.
Patients with MSI-H and BRAF-mutated tumours experienced significantly lower PFS (3.1 vs 11.4 months; P¼0.008) and OS (14.5 vs
35.5 months; P¼0.004) than patients with MSI-H and BRAF wt tumours. Similarly, BRAF mutations and cyclin D1 overexpression
were correlated with decreased PFS (3.1 vs 8.6 months; P¼0.03) and OS (17.8 vs 39.2 months; P¼0.01).
CONCLUSION: BRAF V600E mutations are associated with MSI-H status and cyclin D1 overexpression and characterize a subgroup of
patients with poor prognosis.
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Colorectal cancer (CRC) remains a major public health problem
in the Western world with an estimated 146970 new cases
and 49920 deaths in the United States in 2009 (Jemal et al,
2009). Some molecular markers have already been incorporated in
the treatment of CRC patients. Indeed, the knowledge of KRAS
mutational status of a primary tumour is now mandatory for the
treatment of metastatic disease, as it is a predictor of resistance to
monoclonal antibodies of the epidermal growth factor receptor
(anti-EGFR moAbs) (Bokemeyer et al, 2008; Douillard et al, 2009;
Hecht et al, 2009; Tol et al, 2009; Van Cutsem et al, 2009). In
addition, BRAF V600E mutation identifies a subgroup (o10%) of
patients with unfavourable prognosis (Di Nicolantonio et al, 2008;
Souglakos et al, 2009); conversely, the presence of a defective
tumoural DNA mismatch repair (dMMR) system seems to be a
favourable prognostic factor (French et al, 2008), although these
patients seem to respond worse to standard adjuvant chemotherapy
(Hemminki et al, 2000; Samowitz et al, 2001; Popat et al, 2005;
French et al, 2008).
The RAS–RAF–MEK–ERK–MAP kinase pathway mediates
cellular responses to growth signals constituting an essential
component of intracellular signalling from activated cell-surface
receptors to transcription factors in the nucleus (Peyssonnaux and
Eychene, 2001). In the BRAF gene, one of the three RAF genes and
part of the above-mentioned pathway, the single substitution
missense mutation V600E, located within the kinase domain,
account for more than 80% of the described mutations. The BRAF
V600E mutation has been detected in a wide range of human
cancers, including melanomas, thyroid carcinomas, sporadic CRC
(10%) and others. The V600E mutation results in a constitutive
activation of the BRAF kinase promoting cell transformation
(Davies et al, 2002; Preto et al, 2008).
In a retrospective study of sporadic metastatic colorectal cancer
(mCRC), BRAF mutations, detected in 8% of patients, were
emerged as an independent prognostic factor for both progression-
free survival (PFS) and overall survival (OS) (Souglakos et al,
2009). Similar findings were reported by Di Nicolantonio et al
(2008) who concluded that the BRAF V600E mutation is not only
inversely associated with response to anti-EGFR moAb therapy,
but it is also associated with a worse prognosis.
The microsatellite instability (MSI), which is characterised by
the absence of protein expression encoded by the corresponding
MMR genes (hMLH1, hMSH2, hMSH6 or PMS2; Thibodeau et al,
1993, 1998; Popat et al, 2005), is observed in nearly all patients
with CRC due to hereditary non-polyposis colon cancer (HNPCC)
(Aaltonen et al, 1993, 1994; Thibodeau et al, 1993) and in 15–20%
of patients with sporadic CRC (Aaltonen et al, 1993). In its familial
form, the genetic basis of instability is mainly (80%) inherited
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sgerm-line mutations of the MMR genes (especially hMLH1 and
hMSH2; Leach et al, 1993; Peltomaki, 1994), whereas in the
sporadic form, it is due to hMLH1 inactivation by epigenetic
hypermethylation of the promoter and less frequently to genetic
alterations of hMSH2 and hMSH6 genes (Kane et al, 1997;
Cunningham et al, 1998, 2001; Thibodeau et al, 1998). Microsatellite
genotyping of CRC patients for clinically applicable diagnosis is
based on specific standard criteria using specific panels (Boland
et al, 1998). Since then, these panels have been clinically applicable
for the diagnosis of CRC patients (Gryfe et al, 2000; Watanabe
et al, 2001).
In CRC tumours, BRAF mutations seem to occur more
frequently in cases characterised by dMMR (Rajagopalan et al,
2002). Moreover, several studies suggest that the BRAF V600E
mutation occurs much more frequently in MSI-H tumours in
comparison with microsatellite stable (MSS) tumours (50 vs o5%
respectively) (Wang et al, 2003; Domingo et al, 2004).
Cyclin D1 is a cell-cycle regulatory protein and its upregulation
has been associated with increased proliferation and poor clinical
outcome in various tumours (Le Marchand et al, 2003). Cyclin D1
is a key element in the downstream EGFR signalling pathway;
KRAS mutations lead to the activation of the RAS–RAF–MEK–
ERK–MAP kinase pathway by inducing cyclin D1 synthesis
(Kobayashi et al, 2006). BRAF controls proliferation of human
melanoma cells through the regulation of cyclin D1 and cyclin-
dependent kinase inhibitor p27
Kip1 protein (Bhatt et al, 2005,
2007). Similarly, it has been reported that in CRC cells the
decreased expression levels of pERK protein and cyclin D1 were
more pronounced in cells carrying the BRAF V600E mutation,
and, that BRAF V600E–ERK signalling is also important in the
regulation of proliferation by p27
Kip1 and cyclin D1 proteins in
these cells (Preto et al, 2008).
The aim of this study was to investigate the clinical relevance of
BRAF V600E mutation status, cyclin D1 expression and MSI status
of primary tumours of patients with mCRC treated with front-line
5FU-based chemotherapy.
MATERIALS AND METHODS
Patient population and study design
A total of 144 consecutive patients, with histologically confirmed
mCRC and available tumour material for molecular analysis, who
were treated at the University Hospital of Heraklion (Crete,
Greece) between January 2002 and December 2006 were enrolled.
The study was approved by the institutional ethics committee and
all patients gave the informed consent for the use of the tissue
material for translational research.
The majority of patients were treated in the context of
two clinical trials conducted at our centre (Souglakos et al,
2006; Emmanouilides et al, 2007; Tables 1 and 2). Patients were
evaluated at baseline and every four cycles of chemotherapy.
Disease status was coded, without the knowledge of the laboratory
analysis.
Tissue selection and DNA extraction
Formalin-fixed, paraffin-embedded tumour sections were reviewed
by a pathologist (MT) to confirm the diagnosis and define tumour-
enriched areas for dissection. Ten serial sections of 5mm thickness
were stained with nuclear fast red (Sigma-Aldrich, St Louis, MO,
USA) and scrape dissection under a binocular microscope was
performed for samples with X80% tumour cells; for samples with
o80% malignant cells, microdissection with the piezoelectric
Eppendorf microdissector (Eppendorf, Hamburg, Germany) was
performed. Isolated cancer cells were lysed in buffer containing
Proteinase K at 601C for 72h, followed by DNA extraction using
the MasterPure Complete DNA and RNA Purification Kit according
to the manufacturer’s instructions (Epicentre Biotechnologies,
Madison, WI, USA).
BRAF testing
The V600E BRAF mutation was detected by real-time PCR
using the allelic discrimination method as previously described
(Benlloch et al, 2006). In brief, the DNA extracted from tumoural
cells was amplified with the use of a set of primers and two
hydrolysis probes in the ABI PRISM 7900T Sequence Detection
System (Applied Biosystems, Forest City, CA, USA). The two
hydrolysis probes were labelled at 5 with VIC and FAM
fluorophores reporters for the wild-type (wt) and the mutant
allele respectively. The SDS 2.3 software (Applied Biosystems) was
used for the analysis of the results.
Immunohistochemistry for MMR and cyclin D1
Tumour sections form each patient were selected for immuno-
histochemical staining using anti-hMLH1 and anti-hMSH2 (for the
MMR definition as previously described; Lindor et al, 2002) and
anti-cyclin D1 (Nosho et al, 2008) antibodies. In brief, immuno-
staining was performed using the UltraVision LP Large Volume
Detection System AP Polymer (Thermo Scientific, Waltham, MA,
USA). The primary antibodies and their corresponding dilutions
used were: hMLH1 (Cell Marque, Rocklin, CA, USA; dilution
1:50), hMSH2 (Cell Marque Rocklin; dilution 1:50) and Cyclin D1
(Neomarker, Fermont, CA, USA; dilution 1:25). Nuclear immu-
nostaining of lymphocytes and stromal cells served as internal
positive control for hMLH1 and hMSH2. Tumours showing loss of
nuclear hMSH2 or hMLH1expression were classified as hMLH1 or
hMSH2 negative. In addition, for cyclin D1 a positive control slide
from a case of mantle cell lymphoma was included and nuclear
immunostaining was considered positive. Negative control slides
were prepared by omitting the primary antibody. Nuclear cyclin
D1 expression was recorded as no expression, weak expression or
moderate/strong expression. Cyclin D1 overexpression was defined
as X50% of tumour cells with weak nuclear staining or X20%
of tumour cells with moderate/strong nuclear staining (Nosho
et al, 2008).
MSI testing and mismatch repair definition
Microsatelite instability status was evaluated in all samples using
the five microsatellite markers of the NCI reference panel (BAT-25
at 4q12, BAT-26 at 2p16, D2S123 at 2p16-p21, D5S346 at 5q21-q22
and D17S250 at 17q11.2-q12) and with two additional micro-
satellite markers of the alternative panel (D18S58 at 18q22-q23
and D18S61 at 18q22) (Boland et al, 1998). PCR for the above-
mentioned microsatellite markers was carried out on tumour and
matched DNA from the adjacent normal colonic tissue. Standard
PCR conditions were used and included 10  buffers, Taq gold
and deoxynucleotide triphosphates adjusted to a final reaction
volume of 25ml containing 100ng of genomic DNA (Boland et al,
1998; Watanabe et al, 2001).
Single-strand conformation polymorphism in non-denaturing
environment (Makino et al, 1992) was performed after optimisa-
tion with a 7% polyacrylamide gel (5% glycerol) for the analysis of
BAT-25 and BAT-26 PCR products. The PCR products of other
microsatellite markers’ were analysed in 7% polyacrylamide gels
and silver-stained. Gels were scanned and the intensity of the
bands corresponding to the microsatellite alleles was quantified by
a digital image analysis system, as previously described (Saridaki
et al, 2003). The analysis was repeated at least twice and the same
results were obtained in all cases. MSI was diagnosed in case of
an addition or deletion of one or more repeat units resulting
in novel alleles. All the heterozygous cases, and those that were
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counted to estimate the MSI rate. If X30% of the loci examined
showed MSI, the tumour was classified as MSI-H. If o30% of the
loci examined showed MSI, it was classified as MSI-L and if none
of the examined loci showed instability, the tumour was classified
as MSS (Boland et al, 1998).
Table 1 Characteristics of enrolled patients and univariate analysis for PFS and OS
N
First-line progression-free survival Overall survival
Feature 144 % Median (months) HR (95% CI) P-value Median (months) HR (95% CI) P-value
Median age (range) 64 (23–81)
p65 years 76 53 9.7 1.3 (0.9–1.8) 0.1 32.2 1.1 (0.8–1.7) 0.5
465 years 68 47 8.1 29.3
Gender
Male 82 57 8.9 1.3 (0.9–1.8) 0.2 30.2 1.2 (0.8–1.7) 0.5
Female 62 43 10.3 32.1
Stage at diagnosis
I–III 82 57 9.4 1.1 (0.7–1.7) 0.9 31.3 1.4 (0.8–2.3) 0.2
IV 62 43 8.1 32.1
Tumour location
Colon 105 73 9.8 1.3 (0.6–2.6) 0.5 29.8 1.7 (0.7–4.6) 0.3
Rectum 39 27 10.4 31.9
Number of treatment lines Median: 3
1 29.8
2 34.8 0.8 (0.5–1.5) 0.6
3 44.2 0.4 (0.2–0.0) 0.02
Histological grade
I–II 107 74 12.2 2.0 (1.3–3.2) 0.001 39.2 2.7 (1.6–4.4) o0.001
III 37 26 7.6 23.8
Adjuvant treatment
Yes 58 40 9.5 1.2 (0.6–2.5) 0.5 31.6 1.1 (0.6–1.8) 0.9
No 86 60 10.2 31.4
Metastasectomy
Yes 21 15 24.2 0.5 (0.2–0.7) o0.001 48.7 0.6 (0.2–0.9) 0.03
No 123 85 9.1 31.4
BRAF status
Mutant 12 8 2.7 2.9 (1.6–5.4) o0.001 14.0 4.3 (2.3–8.2) o0.001
Wt 132 92 9.8 30.3
MSI status
High 22 15 9.7 1.0 (0.7–1.7) 0.8 21.3 1.3 (0.8–2.1) 0.3
Stable 122 85 10.4 30.2
Cyclin D1
Overexpression 26 18 8.3 0.8 (0.5–1.4) 0.1 21.7 1.1 (0.6–1.8) 0.7
Weak expression 63 44 9.1 29.1
No expression 55 38 11.5 30.3
Abbreviation: MSI¼microsatellite instability.
Table 2 BRAF mutation and MSI status and correlations with PFS and OS
MSI-H, n¼22 (15%) MSS, n¼122 (85%)
Total (n¼144) N (%) Median (months) N (%) Median (months) P-value
Progression-free survival
BRAF mutant, n¼12 (8%) 10 (45) 3.1 2 (1.6) 1.6 0.003
&
BRAF wt, n¼132 (92%) 12 (55) 11.4 120 (98.4) 9.7 0.2
@
P-value 0.008* o0.001
#
Median overall survival
BRAF mutant, n¼12 (8%) 10 (45) 14.5 2 (1.6) 2.6 0.05
&
BRAF wt, n¼132 (92%) 12 (55) 35.5 120 (98.4) 30.2 0.4
@
P-value 0.004* o0.001
#
Abbreviation: MSI¼microsatellite instability. *P-value: MSI-H BRAF mutant vs MSI-H BRAF wt.
#P-value: MSS BRAF mutant vs MSS BRAF wt.
&P-value: MSI-H BRAF mutant vs MSS
BRAF mutant.
@P-value: MSI-H BRAF wt vs MSS BRAF wt.
BRAF, MSI status, cyclin D1 expression in CRC
Z Saridaki et al
1764
British Journal of Cancer (2010) 102(12), 1762–1768 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sStatistical analysis
Associations between BRAF mutation status, dMMR, cyclin D1
expression and baseline characteristics were assessed using the
Fisher’s exact test for categorical variables or logistic regression for
continuous variables. PFS was measured from the date of first-line
therapy initiation to the first radiographic documentation of
disease progression or death, and OS was calculated from the
date of diagnosis of metastatic disease to death due to mCRC.
Kaplan–Meier curves were used to describe the proportion of
patients who remained free of events over the follow-up period.
Associations between prognostic factors and PFS or OS were
examined using Cox proportional hazards regression models. All
reported P-values are two sided and not adjusted for multiple testing.
RESULTS
The median age of patients was 64 years and 57% of them were
men. Metastasectomy was also performed in 21 (15%) patients
(Tables 1 and 2). The BRAF V600E mutation was detected in
12 (8%) patients and 22 (15%) tumours were characterised as
MSI-H. MSI analysis using immunohistochemistry and mole-
cular techniques presented 100% accordance (Figure 1A and B).
Cyclin D1 was overexpressed in 26 (18%) patients, weakly
expressed in 63 (44%) and not expressed in 55 (38%) (Figure 1C).
There was no correlation between the presence of BRAF muta-
tion, MSI-H and cyclin D1 expression, and the patient’ gender,
age, stage at diagnosis, histological grade and tumour location
(all P-values 40.05).
The median time from initial diagnosis to diagnosis of
metastatic disease was 19.3 months (95% CI 14.6–20.3) for
patients with early stage disease and the median interval from
the diagnosis of metastatic disease to treatment initiation 0.8
months (95% CI 0.5–1.1). All patients were treated with
5-FU-based first-line chemotherapy with or without moAb supple-
mentation (Table 3). At the time of analysis 132 out of 144 (92%)
patients were dead, 128 (97%) of them due to disease progression,
2 (1.5%) due to toxicity and 2 (1.5%) due to reasons unrelated with
disease or treatment.
BRAF mutations were present in 45 and 1.6% of the patients
with MSI-H and MSS tumours respectively (Po0.001). The
detection of BRAF mutations was also correlated with cyclin D1
expression as cyclin D1 overexpression was detected in 58 and 14%
of BRAF mutated and wt tumours respectively (P¼0.001; Table 4).
The median PFS of the whole group of patients was 9.5 months
(95% CI 8.4–10.8) and the corresponding median OS was 31.5
months (95% CI 26.4–37.7). The median OS was 14 and 30 months
for patients with BRAF-mutated and wt tumours respectively
(Po0.001; Figure 2A). In addition, PFS was 2.7 and 9.8 months for
patients with BRAF-mutated and wt primary tumours respectively
(Po0.001; Figure 2B). Patients with MSI-H and BRAF-mutated
tumours experienced significantly lower PFS (3.1 vs 11.4 months;
P¼0.008) and OS (14.5 vs 35.5 months; P¼0.004) in comparison
with those with MSI-H and BRAF wt tumours. Similarly, BRAF
mutations and cyclin D1 overexpression were correlated with
decreased PFS (3.1 vs 8.6 months; P¼0.03) and OS (17.8 vs 39.2
months; P¼0.01).
Univariate analysis (Tables 1 and 2) revealed significant
associations of PFS with undifferentiated tumour histology
(P¼0.001), BRAF mutations (Po0.001) and inability of patients
to undergo metastasectomy (Po0.001). In addition, univariate
analysis showed significant associations between OS and
(1) tumour differentiation (grade 3) (PFS and OS: Po0.001); (2) BRAF
mutations (Po0.0001), (3) metastasectomy (OS: P¼0.03) and
(4) the sum of treatment lines that a patient had the opportunity
to receive (P¼0.02).
In multivariate analysis, BRAF mutation and tumour grade
were emerged as independent prognostic factors for reduced PFS
(HR 2.8, 95% CI 1.4–5.7, P¼0.004 and HR 2.0, 95% CI 1.3–3.2,
P¼0.001 respectively) and OS (HR 5.3, 95% CI 2.5–11.3, Po0.001
and HR 2.6, 95% CI 1.6–4.4, Po0.001 respectively). In addition,
both metastasectomy and the number of administered treatment
A
B
C
Figure 1 (A) MLH1(þ) adenocarcinoma with moderate differentiation
of the colon (original magnification,  200). (B) MSH2(þ) adenocarci-
noma with moderate differentiation of the colon (original magnification,
 100). (C) Cyclin D1( þ) adenocarcinoma moderate–poorly differentiated
(original magnification,  100).
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PFS and OS (Table 5).
In addition, 48 (33%) patients were treated with cetuximab, 11
in the 1st line setting and 37 in 2nd and further lines. KRAS
mutational status was available in 42 of these patients and 13
(31%) of them carried a mutation in their primary tumours. KRAS
and BRAF mutation were found to be mutually exclusive. KRAS
status predicted resistance to cetuximab therapy in terms of
decreased PFS (P¼0.045) and mOS (P¼0.007). Also, four (8.5%)
patients were found to harbour a BRAF
V600E mutation in the
primary tumours. Similarly, patients with a BRAF mutation
presented lower PFS (P¼0.05) and mOS (P¼0.004). When
analysed together, the presence of either mutation was significantly
correlated with decreased PFS (P¼0.013) and mOS (P¼0.003) in
cetuximab-treated patients. BRAF mutation retains its prognostic
significance in PFS (0.003) and mOS (o0.001) in the subpopula-
tion of patients that have not received cetuximab in the course of
their disease.
DISCUSSION
The results of this study show that patients with BRAF-mutated
tumours had a significantly lower median PFS and OS compared
with patients with wt tumours. In addition, multivariate analysis
revealed that the presence of the V600E BRAF mutation was
established as an independent prognostic factor for reduced PFS
and OS. Similar results have been previously reported regarding
the prognostic of BRAF mutation in patients with mCRC
(Samowitz et al, 2005; Souglakos et al, 2009). In this study,
median OS was 31.5 months, which is higher than survival
reported by other studies. This improved OS could be related to
the fact that after initial response to systemic treatment, 24% of
patients underwent metastasectomy; alternatively, we cannot
exclude that this observation may be due the fact that 87% of
the patients had received all three chemotherapeutic drugs in the
course of their treatment (Grothey et al, 2004; Hurwitz et al, 2004)
whereas 45% of patients had also received both moAbs as well.
In this study, the incidence of BRAF mutations was significantly
higher in patients with MSI-H (45%) than with MSS tumours
(1.6%; P¼o0.001), in agreement with the published evidence
(Rajagopalan et al, 2002; Oliveira et al, 2003; Wang et al, 2003).
Moreover, our patients with MSI-H and BRAF-mutated tumours
Table 3 Treatment regimens used in this retrospective study
First-line regimens N (out of 144) %
FOLFOX+Bevacizumab 33 23
FOLFOX+Cetuximab 9 6
FOLFOXIRI 67 46
FOLFIRI 27 19
FOLFOX 8 6
Oxaliplatin-based treatment (first line) 117 82
Irinotecan-based treatment (first line) 94 65
Bevacizumab+chemotherapy (first line) 33 23
Oxaliplatin-based treatment (any line) 128 89
Irinotecan-based treatment (any line) 123 85
Bevacizumab+chemotherapy (any line) 74 51
Cetuximab+chemotherapy (any line) 69 48
Patients treated with all 3 chemotherapy drugs 126 87
Patients treated with all 5 active agents 65 45
Abbreviations: FOLFOX¼folinic acid, 5FU, oxaliplatin; FOLFIRI¼folinic acid, 5FU,
irinotecan; FOLFOXIRI¼folinic acid, 5FU, oxaliplatin, irinotecan.
Table 4 Correlations of BRAF mutations with MSI status and cyclin D1 expression in 144 patients
MSI status, N (%) Cyclin D1, N (%)
High Stable Overexpressed Weak expression No expression
No of patients 22 (15) 122 (85) P-value
a 26 (18) 63 (44) 55 (38) P-value
a
BRAF V600E mutation
Mutant 12 10 (83) 2 (17) o0.001 7 (58) 3 (25) 2 (17) 0.001
b
Wild type 132 12 (9) 120 (91) 19 (14) 60 (46) 53 (40)
Abbreviation: MSI¼microsatellite instability.
aFisher’s exact test.
bOverexpression vs weak or no expression.
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Figure 2 (A) Progression-free survival in first-line chemotherapy,
analysed by BRAF mutation status. (B) Overall survival, analysed by BRAF
mutation status.
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sexperienced significantly lower PFS (P¼0.008) and OS (P¼0.004)
in comparison with those with MSI-H and BRAF wt primary
tumours. Similar results have been reported regarding the
prognostic significance of BRAF mutations in patients with early
stage CRC (Samowitz et al, 2005; French et al, 2008). In the French
et al (2008) trial among patients with dMMR, BRAF wt cases had a
significantly improved OS compared with those that were BRAF
mutated (P¼0.001). Samowitz et al (2005) showed that patients
with dMMR tumours were associated with an excellent 5-year OS
regardless of the BRAF V600E status. However, they have also
reported that the BRAF mutation was associated with poor survival
among the patients with MSS tumours (Samowitz et al, 2005).
Nevertheless, the direct comparison of these studies is difficult
because of differences in the studied population, and additional
studies with larger groups of patients are required.
In this study, the detection of BRAF mutations was associated
with cyclin D1 expression. Indeed, the incidence of cyclin D1
overexpression was significantly higher in BRAF-mutated (58%)
than BRAF wt tumours (14%; P¼0.001), and patients with
BRAF mutations and cyclin D1 overexpression had significantly
decreased PFS (P¼0.03) and OS (P¼0.01) compared with patients
with BRAF wt tumours. The biological significance of the BRAF
V600E mutation and oncogenic activation in MSI-H CRC is not
well established. The effect of BRAF knockdown in cellular survival
and proliferation is not fully understood. It has been shown that in
MSI CRC cell lines, BRAF is the main activator of ERKs and these
cells are more dependant on the BRAF–ERK pathway (Preto et al,
2008). Similar to the melanoma model (Bhatt et al, 2005, 2007), in
MSI CRC cells, it was shown that BRAF V600E–ERK signalling is
important in the regulation of proliferation through the p27
Kip1 and
cyclin D1 proteins (Preto et al, 2008).
Furthermore, the presence of BRAF mutations has been
correlated with resistance to the anti-EGFR moAb cetuximab
(Di Nicolantonio et al, 2008; Souglakos et al, 2009). Moreover,
the introduction/presence of the BRAF V600E allele in CRC
(DiFi-BRAF, COLO-205 and HT-29) cell lines impaired the
therapeutic potential of anti-EGFR moAbs. In contrast, when
these cells lines were treated with a combination of cetuximab and
the small-molecule kinase BRAF inhibitor, sorafenib, a significant
reduction in proliferation and a prominent proapoptotic effect was
found, whereas, either of these agents alone had limited effects
(Di Nicolantonio et al, 2008). Thus, in the clinical setting, the
therapeutic effect of anti-EGFR moAbs could be restored by a
two-hit approach that blocks the EGFR pathway in multiple
locations. In accordance with previous reports (Di Nicolantonio
et al, 2008; Souglakos et al, 2009), we found that BRAF mutation
predicted resistance to cetuximab treatment in the subpopulation
of patients that have received this kind of therapy. Furthermore,
the prognostic impact of BRAF mutation remains significant not
only in the whole of the study but also in the subpopulation of
patients that have not received an anti-EGFR moAbs.
In summary, BRAF V600E mutations, which are correlated
with MSI-H status and cyclin D1 overexpression, characterise a
subgroup of patients with poor prognosis. The findings reported in
this study confirm our previous observations (Souglakos et al,
2009) as well as from other groups (Samowitz et al, 2005).
Nevertheless, they need to be formally confirmed in prospective
randomised clinical trials, as this subgroup of patients might
justify foregoing approved treatments in favour of investigational
ones. Furthermore, the adverse significance of BRAF mutations
could be used to stratify patients in future clinical trials because
these patients carry a significant higher risk of progression and
death due to the disease.
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